MX2015017972A - Cristales de base libre. - Google Patents
Cristales de base libre.Info
- Publication number
- MX2015017972A MX2015017972A MX2015017972A MX2015017972A MX2015017972A MX 2015017972 A MX2015017972 A MX 2015017972A MX 2015017972 A MX2015017972 A MX 2015017972A MX 2015017972 A MX2015017972 A MX 2015017972A MX 2015017972 A MX2015017972 A MX 2015017972A
- Authority
- MX
- Mexico
- Prior art keywords
- free base
- crystals
- base crystals
- methyl
- zolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838105P | 2013-06-21 | 2013-06-21 | |
| US201361919424P | 2013-12-20 | 2013-12-20 | |
| PCT/US2014/043422 WO2014205354A2 (en) | 2013-06-21 | 2014-06-20 | Free base crystals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015017972A true MX2015017972A (es) | 2016-10-28 |
Family
ID=52105535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017972A MX2015017972A (es) | 2013-06-21 | 2014-06-20 | Cristales de base libre. |
| MX2020001628A MX2020001628A (es) | 2013-06-21 | 2015-12-21 | Cristales de base libre de (6ar, 9as)-5,6a,7,8,9,9a-hexahidro-5-me til-3-(fenilamino-2-((4-((6-fluoropiridin-2-il)fenil)metil)-ciclo pent[4,5]imidazo[1,2-a]pirazolo[4,3-e]pirimidin-4(2h)-ona. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001628A MX2020001628A (es) | 2013-06-21 | 2015-12-21 | Cristales de base libre de (6ar, 9as)-5,6a,7,8,9,9a-hexahidro-5-me til-3-(fenilamino-2-((4-((6-fluoropiridin-2-il)fenil)metil)-ciclo pent[4,5]imidazo[1,2-a]pirazolo[4,3-e]pirimidin-4(2h)-ona. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9630971B2 (enExample) |
| EP (2) | EP3010509B1 (enExample) |
| JP (2) | JP6865036B2 (enExample) |
| KR (2) | KR102430126B1 (enExample) |
| CN (3) | CN105658222A (enExample) |
| AU (1) | AU2014284224B2 (enExample) |
| BR (1) | BR112015032132B1 (enExample) |
| CA (1) | CA2916393C (enExample) |
| ES (1) | ES2894770T3 (enExample) |
| IL (2) | IL267331B2 (enExample) |
| MX (2) | MX2015017972A (enExample) |
| RU (1) | RU2675851C2 (enExample) |
| WO (1) | WO2014205354A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2717877B1 (en) | 2011-06-10 | 2017-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AR091507A1 (es) * | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| EP3010509B1 (en) | 2013-06-21 | 2021-07-28 | Intra-Cellular Therapies, Inc. | Free base crystals |
| US12410175B2 (en) | 2019-09-03 | 2025-09-09 | Intra-Cellular Therapies, Inc. | Compounds |
| US12435093B2 (en) | 2020-05-06 | 2025-10-07 | Intra-Cellular Therapies, Inc. | Free base crystals |
| WO2022026417A1 (en) * | 2020-07-26 | 2022-02-03 | Intra-Cellular Therapies, Inc. | Novel uses |
| JP2024531548A (ja) * | 2021-09-03 | 2024-08-29 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 共結晶 |
| WO2023147484A1 (en) * | 2022-01-27 | 2023-08-03 | Intra-Cellular Therapies, Inc. | Novel compositions |
| WO2023147603A2 (en) * | 2022-01-31 | 2023-08-03 | Intra-Cellular Therapies, Inc. | Salt crystals |
| WO2023233410A1 (en) * | 2022-06-02 | 2023-12-07 | Biosight Ltd. | Crystalline form of aspacytarabine intermediate |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9412571D0 (en) * | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| US5471001A (en) * | 1994-12-15 | 1995-11-28 | E. I. Du Pont De Nemours And Company | Crystallization of adipic acid |
| GB9624615D0 (en) * | 1996-11-26 | 1997-01-15 | Zeneca Ltd | Chrystallisation process |
| TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| ATE496028T1 (de) * | 2002-02-08 | 2011-02-15 | Ono Pharmaceutical Co | Piperidinderivatverbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten |
| EP1613747A1 (en) | 2003-03-31 | 2006-01-11 | Pfizer Products Inc. | Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
| CN100457108C (zh) * | 2003-09-02 | 2009-02-04 | 默克公司 | 一种二肽基肽酶iv抑制剂的磷酸盐新晶体 |
| CN101031548B (zh) * | 2004-09-27 | 2011-04-06 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备 |
| WO2006133261A2 (en) | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2008063505A1 (en) | 2006-11-13 | 2008-05-29 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
| EP2939676A1 (en) * | 2007-12-06 | 2015-11-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US20120070443A1 (en) | 2008-12-02 | 2012-03-22 | University Of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
| EA201170769A1 (ru) | 2008-12-06 | 2012-02-28 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| AU2009322903A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PE20110922A1 (es) * | 2008-12-06 | 2012-01-22 | Intra Cellular Therapies Inc | DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1) |
| WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
| EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| US8858911B2 (en) | 2009-10-08 | 2014-10-14 | Intra-Cellular Therapies, Inc. | Phosphodiesterase 1-targeting tracers and methods |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
| EP2717877B1 (en) | 2011-06-10 | 2017-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AR091507A1 (es) * | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| EP3010509B1 (en) | 2013-06-21 | 2021-07-28 | Intra-Cellular Therapies, Inc. | Free base crystals |
-
2014
- 2014-06-20 EP EP14812994.3A patent/EP3010509B1/en active Active
- 2014-06-20 JP JP2016521847A patent/JP6865036B2/ja active Active
- 2014-06-20 US US14/900,589 patent/US9630971B2/en active Active
- 2014-06-20 CN CN201480046150.4A patent/CN105658222A/zh active Pending
- 2014-06-20 IL IL267331A patent/IL267331B2/en unknown
- 2014-06-20 EP EP20165092.6A patent/EP3702358A1/en active Pending
- 2014-06-20 WO PCT/US2014/043422 patent/WO2014205354A2/en not_active Ceased
- 2014-06-20 BR BR112015032132-1A patent/BR112015032132B1/pt active IP Right Grant
- 2014-06-20 MX MX2015017972A patent/MX2015017972A/es active IP Right Grant
- 2014-06-20 AU AU2014284224A patent/AU2014284224B2/en active Active
- 2014-06-20 CA CA2916393A patent/CA2916393C/en active Active
- 2014-06-20 KR KR1020217030964A patent/KR102430126B1/ko active Active
- 2014-06-20 KR KR1020167001273A patent/KR20160040522A/ko not_active Ceased
- 2014-06-20 CN CN201910526464.9A patent/CN110498800A/zh active Pending
- 2014-06-20 CN CN202110144523.3A patent/CN112851683A/zh active Pending
- 2014-06-20 RU RU2016101630A patent/RU2675851C2/ru active
- 2014-06-20 ES ES14812994T patent/ES2894770T3/es active Active
-
2015
- 2015-12-21 MX MX2020001628A patent/MX2020001628A/es unknown
- 2015-12-21 IL IL243269A patent/IL243269B/en active IP Right Grant
-
2019
- 2019-06-04 JP JP2019104412A patent/JP2019189618A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX352831B (es) | Cristales de sal. | |
| BR112015032132A2 (pt) | cristais de base livre | |
| HUE059274T2 (hu) | Imidazo[4,5-d]pirrolo[2,3-b]piridin-származékok mint janus-kinázok inhibitorai | |
| IL241573B (en) | Transformed histories of [2h]imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidine-4[5h]-one, a pharmaceutical preparation containing them and their use as drugs | |
| PE20151755A1 (es) | Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos | |
| IL288674B (en) | 7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidine-5(1h)one, its salts and methods Use | |
| EP2931722A4 (en) | SUBSTITUTED 1H-PYRROLO- [2,3-B] PYRIDINE AND 1H-PYRAZOLO- [3,4-B] PYRIDINE DERIVATIVES AS SALT-INDUCIBLE KINASE-2 (SIK2) INHIBITORS | |
| MX370000B (es) | Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selectivos del receptor de nk-3, composición farmacéutica y métodos para su uso en trastornos mediados por el receptor de nk-3. | |
| DK2968294T3 (da) | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on til anvendelse i behandlingen af cancer | |
| HRP20171724T1 (hr) | Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze | |
| MX2016008445A (es) | Derivados de pirazolo [1,5-a] piridina y metodos para su uso. | |
| LT3290421T (lt) | Pirolo [2, 3 -d]pirimidino darinių derinys su vienu arba daugiau papildomų agentų, kaip janus kinazės (jak) inhibitorių | |
| IL243092B (en) | New triazolo[d–4,5]pyrimidine histories | |
| LT2935274T (lt) | 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidino dariniai, skirti kvėpavimo organų ligų gydymui | |
| PE20171104A1 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| MX2015014081A (es) | Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor de canabinoides 2 (cb2). | |
| IL234772A0 (en) | History of 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo, thiano or pyrrolo)[3,2-d]pyrimidin-4-one for cancer treatment | |
| IL246034B (en) | History of [1,2,4]triazolo[1,5-a]pyrimidine as protozoan proteasome inhibitors for the treatment of parasitic diseases such as Jericho | |
| MA45048A (fr) | Nouveau dérivé de 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one | |
| IL237677A0 (en) | Process for preparing 2-amino-8,5-dimethoxy[4,2,1]triazolo[5,1-c]pyrimidine from 4-chloro-5,2-dimethoxypyrimidine | |
| CR20140260A (es) | Composiciones farmaceuticas de 7-(6- (2-hidroxi propan -2-il) piridin -3-il) -1- ((trans) -4-metoxiciclohexil ) -3, 4- dihidropiracino [2,3-b] piracin-2 (1h) -ona, una forma solida de las mismas y metodos de su uso | |
| TH1501001335A (th) | กระบวนการที่ปรับปรุงแล้วสำหรับการเตรียมของ 2-อะมิโน-5,8-ไดเมธอกซิ[1,2,4]ไทรอะโซโล[1,5-c]ไพริมิดีนจาก 4-อะมิโน-2,5-ไดเมธอกซิไพริมิดีน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |